Potomac Urology is the first in Woodbridge, VA to Offer Aquablation Therapy, a New, Minimally Invasive, Robotic Treatment for Enlarged Prostates that Provides BPH Relief without Compromise
Woodbridg, VA, July 13, 2021 – Potomac Urology announced today that it is the first in Woodbridge, VA to offer Aquablation therapy for the treatment of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH).
BPH, or an enlarged prostate, is a non-cancerous condition where the prostate has grown to be larger than normal. 1 in 2 men ages 51 to 60 have BPH, and the incidence increases every decade of life.1 If left untreated,
BPH can cause significant health problems, including irreversible bladder or kidney damage, bladder stones, and incontinence. The problem with BPH surgical treatments today is that they often force men to trade off between symptom relief and side effects, limiting patients to choose between either a high degree of symptom relief with high rates of irreversible complications (such as incontinence, erectile dysfunction, or ejaculatory dysfunction) or low degree of symptom relief with low rates of irreversible complications.
Aquablation therapy is a different type of treatment for BPH. It’s an advanced, minimally invasive treatment that uses the power of water delivered with robotic precision to provide best-in-class and long-lasting symptom relief with low rates of irreversible complications, regardless of prostate size or shape.2,3
QUOTE: “We are proud to be among the first in [name of city, state, region] to offer a solution for men with BPH that provides BPH relief without compromise,” said [name]. “Aquablation therapy is the next step to furthering our commitment to robotic surgery and men’s health” [insert details about the clinical outcomes or patient experiences seen with Aquablation therapy and any additional program/initiative details].
Aquablation therapy is performed by the AquaBeam Robotic System, the first FDA-cleared, surgical robot utilizing automated tissue resection or the treatment of LUTS due to BPH. It combines real-time, multi-dimensional imaging, automated robotic technology, and heat-free waterjet ablation technology for targeted, controlled,
and immediate removal of prostate tissue. Aquablation therapy offers predictable and reproducible outcomes, independent of prostate anatomy, prostate size, or surgeon experience.
Aquablation therapy has proven results. In clinical studies, Aquablation therapy has shown to provide both best-in- class and durable symptom relief with low rates of irreversible complications.2-4
A study within the Journal of Sexual Medicine, which surveyed 300 men living with BPH, revealed 92% of respondents expressed an interest in learning more about Aquablation therapy.5 This data demonstrates the need within the patient population to find relief without the trade off between symptoms and relief side effects.
[Insert quote from institution spokesperson]
For more information on Potomac Urology visit https://potomacurology.com/services/bph-treatment-options/aquablation/
For more information on Aquablation therapy, visit aquablation.com
About Potomac Urology
Potomac Urology has performed more Aquablation procedures than anyone else in the country
Potomac Urology is an expert urology practice committed to providing the highest quality care to patients here in the Northern Virginia area and nationwide in the diagnosis and treatment of urology related conditions. Our team of urologists are dedicated to offering patients a broad range of quality urology services including BPH treatment options in a warm and friendly environment to provide the very best in urologic care. To learn more about the Aquablation Therapy Surgical Treatment for BPH at our office in Alexandra, VA, call us at to schedule your appointment today.
(Press release continued)
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics is a surgical robotics company enabling better patient care by developing transformative solutions in urology. With an initial focus on BPH, the AquaBeam Robotic System delivering Aquablation therapy is the first FDA-cleared, surgical robot utilizing automated tissue resection for the treatment of lower urinary tract symptoms due to BPH. Aquablation therapy combines real-time, multi-dimensional imaging, automated robotic technology, and heat-free waterjet ablation technology for targeted, controlled, and immediate removal of prostate tissue. Aquablation therapy offers predictable and reproducible outcomes, independent of prostate anatomy, prostate size, or surgeon experience. For more information visit https://www.procept-biorobotics.com.
Important Safety Information
All surgical treatments have inherent and associated side effects. The most common side effects are mild and transient, and may include mild pain or difficulty when urinating, discomfort in the pelvis, blood in the urine, inability to empty the bladder or a frequent and/or urgent need to urinate, and bladder or urinary tract infection. Other risks include ejaculatory dysfunction and a low risk of injury to the urethra or rectum where the devices gain access to the body for treatment. For more information about potential side effects and risks associated with Aquablation therapy, speak with your urologist or surgeon. No claim is made that the AquaBeam Robotic System will cure any medical condition, or entirely eliminate the diseased entity. Repeated treatment or alternative therapies may sometimes be required.
Roehrborn, CG, Rosen, RC. Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily. Clinical Interventions in Aging 2008:3(3).
Gilling, P, et al. Three-Year Outcomes after Aquablation Therapy Compared to TURP: Results from a Blinded Randomized Trial. Can J Urol. 2020 Feb;27(1):10072-10079.
Desai, M, et al. Aquablation for benign prostatic hyperplasia in large prostates (80-150 cc): 2-year results. Can J Urol. 2020 Apr;27(2):10147-10153.
Bach, T, et al. First Multi-Center All-Comers Study for the Aquablation Procedure. J Clin Med. 2020 Feb; 9(2): 603.
Data from a global survey of 300 patients with BPH. Data on file at PROCEPT BioRobotics.